PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis
Europe - BIT:PHN - IT0005274094 - Common Stock
48.725 EUR
+0.27 (+0.57%)
We assign a fundamental rating of 7 out of 10 to PHN. PHN was compared to 14 industry peers in the Personal Care Products industry. Both the health and profitability get an excellent rating, making PHN a very profitable company, without any liquidiy or solvency issues. PHN is valued quite expensive, but it does show an excellent growth. With these ratings, PHN could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year PHN was profitable.
PHN had a positive operating cash flow in the past year.
PHN had positive earnings in each of the past 5 years.
PHN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of PHN (20.41%) is better than 100.00% of its industry peers.
Looking at the Return On Equity, with a value of 38.54%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
PHN has a Return On Invested Capital of 26.24%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PHN is significantly above the industry average of 12.12%.
The last Return On Invested Capital (26.24%) for PHN is above the 3 year average (17.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.41% | ||
| ROE | 38.54% | ||
| ROIC | 26.24% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
1.3 Margins
The Profit Margin of PHN (13.48%) is better than 78.57% of its industry peers.
PHN's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 21.87%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of PHN has remained more or less at the same level.
With an excellent Gross Margin value of 97.04%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
PHN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.87% | ||
| PM (TTM) | 13.48% | ||
| GM | 97.04% |
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PHN is creating value.
PHN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHN has less shares outstanding
PHN has a better debt/assets ratio than last year.
2.2 Solvency
PHN has an Altman-Z score of 8.91. This indicates that PHN is financially healthy and has little risk of bankruptcy at the moment.
PHN's Altman-Z score of 8.91 is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
The Debt to FCF ratio of PHN is 2.70, which is a good value as it means it would take PHN, 2.70 years of fcf income to pay off all of its debts.
PHN has a better Debt to FCF ratio (2.70) than 71.43% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that PHN is not too dependend on debt financing.
PHN has a better Debt to Equity ratio (0.28) than 64.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 2.7 | ||
| Altman-Z | 8.91 |
ROIC/WACC3.32
WACC7.9%
2.3 Liquidity
A Current Ratio of 2.06 indicates that PHN has no problem at all paying its short term obligations.
PHN's Current ratio of 2.06 is amongst the best of the industry. PHN outperforms 92.86% of its industry peers.
A Quick Ratio of 1.75 indicates that PHN should not have too much problems paying its short term obligations.
PHN's Quick ratio of 1.75 is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.20% over the past year.
The Earnings Per Share has been growing by 14.63% on average over the past years. This is quite good.
PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.06%.
The Revenue has been growing by 16.59% on average over the past years. This is quite good.
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
3.2 Future
Based on estimates for the next years, PHN will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.52% on average per year.
Based on estimates for the next years, PHN will show a quite strong growth in Revenue. The Revenue will grow by 12.05% on average per year.
EPS Next Y8.85%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
EPS Next 5YN/A
Revenue Next Year14.06%
Revenue Next 2Y14.01%
Revenue Next 3Y13.43%
Revenue Next 5Y12.05%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 19.89, PHN is valued on the expensive side.
PHN's Price/Earnings ratio is a bit cheaper when compared to the industry. PHN is cheaper than 71.43% of the companies in the same industry.
PHN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.53.
With a Price/Forward Earnings ratio of 20.08, PHN is valued on the expensive side.
PHN's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. PHN is more expensive than 64.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.04. PHN is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.89 | ||
| Fwd PE | 20.08 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit cheaper than 64.29% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 78.57% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.58 | ||
| EV/EBITDA | 11.02 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHN does not grow enough to justify the current Price/Earnings ratio.
PHN has an outstanding profitability rating, which may justify a higher PE ratio.
PHN's earnings are expected to grow with 13.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.25
PEG (5Y)1.36
EPS Next 2Y12.93%
EPS Next 3Y13.52%
5. Dividend
5.1 Amount
PHN has a Yearly Dividend Yield of 2.03%.
PHN's Dividend Yield is comparable with the industry average which is at 2.94.
PHN's Dividend Yield is comparable with the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.03% |
5.2 History
The dividend of PHN is nicely growing with an annual growth rate of 11.21%!
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
40.63% of the earnings are spent on dividend by PHN. This is a bit on the high side, but may be sustainable.
PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP40.63%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
BIT:PHN (10/16/2025, 5:29:46 PM)
48.725
+0.27 (+0.57%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners17.08%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap471.66M
Analysts83.33
Price Target80.58 (65.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.03% |
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP40.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.98%
EPS NY rev (3m)-6.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.53%
Revenue NY rev (3m)-0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.89 | ||
| Fwd PE | 20.08 | ||
| P/S | 2.69 | ||
| P/FCF | 57.58 | ||
| P/OCF | 38.27 | ||
| P/B | 7.7 | ||
| P/tB | 12.64 | ||
| EV/EBITDA | 11.02 |
EPS(TTM)2.45
EY5.03%
EPS(NY)2.43
Fwd EY4.98%
FCF(TTM)0.85
FCFY1.74%
OCF(TTM)1.27
OCFY2.61%
SpS18.09
BVpS6.33
TBVpS3.86
PEG (NY)2.25
PEG (5Y)1.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.41% | ||
| ROE | 38.54% | ||
| ROCE | 45.24% | ||
| ROIC | 26.24% | ||
| ROICexc | 32.19% | ||
| ROICexgc | 49.25% | ||
| OM | 21.87% | ||
| PM (TTM) | 13.48% | ||
| GM | 97.04% | ||
| FCFM | 4.68% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexcg growth 3Y-15.98%
ROICexcg growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 2.7 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 97.13% | ||
| Cap/Sales | 2.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.97% | ||
| Profit Quality | 34.7% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.75 | ||
| Altman-Z | 8.91 |
F-Score7
WACC7.9%
ROIC/WACC3.32
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
EPS Next Y8.85%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
EPS Next 5YN/A
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
Revenue Next Year14.06%
Revenue Next 2Y14.01%
Revenue Next 3Y13.43%
Revenue Next 5Y12.05%
EBIT growth 1Y14.83%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.06%
EBIT Next 3Y16.37%
EBIT Next 5Y9.96%
FCF growth 1Y144.25%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y38.33%
OCF growth 3Y0.14%
OCF growth 5Y11.34%